Roche Acquires Inflazome for ~$450M

 Roche Acquires Inflazome for ~$450M

Roche Acquires Inflazome for ~$450M

Shots:

  • Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones
  • The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors
  • Roche will further advance the NLRP3 inhibitors across a wide variety of indications targeting the unmet medical needs across a wide variety of inflammatory diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Ladder

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post